A beautiful looseleaf they sent over recently for me to review is no exception to this rule. It’s called ‘Drafting Agreements in the Biotechnology and Pharmaceutical Industries‘. It is edited by Mark Anderson and has contributors from France (Cabinet Plasseraud), Germany (Reimann Ostericcieth as well as Answaltskanzlei Strater), Spain (Garrigues), Sweden (Sandart & Partners), The Netherlands (NautaDutilh), the United Kingdom (Anderson & Company) and of course the United States (Marshall, Gerstein & Borun).
The book focuses on agreements that concern the pharmaceutical and biotechnology sectors and in particular, the research, development, testing, manufacture, commercialisation, creation, use, etc of products, services and intellectual property in these sectors.
It contains an extensive commentary as well as sample agreements and clauses (always to be used carefully and in context, of course).
I highly recommend it, click this link to go to the OUP site for more details.
(Oxford are of course the publisher for the mammoth global text on pharmaceutical and biotechnology IP which I’ve been working on as Editor with some of the world’s best IP specialists in this area. It’s due to release in a few months – so look out for it.)